- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07941570
The Impact of Using a Non-motorised Physical Assistance Device on the Prevention of Musculoskeletal Disorders Amongst Care-givers (TM2S)
This experimental study uses a Single-Case Experimental Design (SCED) with multiple baselines across participants to evaluate the impact of a non motorized assistive device (DAP) on muscle effort in care givers during their professional activities. Each participant completes a 12-day protocol consisting of three phases (A1 - B - A2), with the initial baseline (A1, no device) randomized between 2 and 6 days, followed by a 6-day intervention phase (B, wearing the non-motorized DAP), and a final withdrawal phase (A2, no device) adjusted to complete the 12-day period. Muscle effort is continuously quantified as a percentage of maximum voluntary contraction using mechanomyographic sensors (MOTEN Technologies) placed on the lumbar and biceps muscles, as well as the quadriceps at the Fondation Saint-Hélier site.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Bastien Fraudet
- Número de teléfono: +33299295043
- Correo electrónico: bastien.fraudet@fondationsainthelier.com
Ubicaciones de estudio
-
-
-
Landivisiau, Francia
- Fondation Ildys - EHPAD Saint Vincent
-
Contacto:
- Manon Le Goff
- Número de teléfono: +33298028308
- Correo electrónico: manon.legoff@ildys.org
-
Investigador principal:
- Sylvia Courtes
-
Ploemeur, Francia, 56270
- Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles (CMRRF) de Kerpape
-
Contacto:
- Marie Caroline Fortuné
- Número de teléfono: +33297826023
- Correo electrónico: marie-caroline.fortune@vyv3.fr
-
Investigador principal:
- Cécile Diot
-
Rennes, Francia
- Fondation Saint Helier
-
Contacto:
- Estelle Cézé
- Número de teléfono: +33299295043
- Correo electrónico: estelle.ceze@fondationsainthelier.com
-
Investigador principal:
- Estelle Cézé
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Aged 18 years and older.
- Height between 160 cm and 200 cm.
- Professional care-giver working in SMR (Medical and Rehabilitation Care) or medico-social departments of partner healthcare facilities.
- Willing to wear the non-motorized DAP under the conditions defined by the protocol.
- Affiliated with or beneficiary of a national social security scheme.
- Having provided free and informed written consent.
Exclusion Criteria:
- Self-reported back, leg, or knee pathology that raises doubts regarding the safe use of the non-motorized DAP without prior medical clearance.
- Pregnant, parturient, or breastfeeding women.
- Persons deprived of liberty by a judicial or administrative decision (including legal guardianship, trusteeship, or court protection).
- Persons receiving psychiatric care or admitted to a healthcare or social establishment for reasons other than research.
- Persons in emergency situations unable to express prior informed consent.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Non-motorized DAP Intervention
Single group following a 12-day A1-B-A2 SCED protocol. Participants undergo a randomized baseline of 2-6 days without the device (A1), a 6-day intervention phase wearing the non-motorized DAP during work activities (B), and an adjusted withdrawal phase without the device (A2). |
Participants wear a non-motorized device for posture assistance (DAP) during their regular professional activities as nurse's aides for 6 consecutive days (Phase B of the 12-day A1-B-A2 SCED protocol). Muscle effort is continuously monitored using mechanomyographic sensors (MOTEN Technologies).
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Maximum Voluntary Contraction (% MVC) of target muscle groups
Periodo de tiempo: Daily during work hours over the 12-day study protocol
|
Muscle effort is continuously quantified via mechanomyography (MMG) using MOTEN Technologies sensors. The primary outcome is the muscle effort level expressed as a percentage of the individual's maximum voluntary contraction (% MVC) for each monitored muscle group (lumbar and biceps muscles across all sites; quadriceps muscles at the Fondation Saint-Hélier site). Measures are compared across the baseline (A1), intervention (B), and withdrawal (A2) phases. |
Daily during work hours over the 12-day study protocol
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in postural strain measured by mechanomyography (MMG)
Periodo de tiempo: Daily during work hours over the 12-day study protocol
|
Postural strain during daily professional activities is evaluated using mechanomyographic (MMG) sensors (MOTEN Technologies) placed on target muscle groups. Measures are compared across the baseline (A1), intervention (B), and withdrawal (A2) phases. |
Daily during work hours over the 12-day study protocol
|
|
Change in perceived effort score using a Numerical Rating Scale (NRS)
Periodo de tiempo: Twice daily (after each half-day work shift) over the 12-day study protocol
|
Perceived exertion during work tasks is assessed using a 0 to 10 Numerical Rating Scale (NRS/EVN), where 0 represents very low effort and 10 represents very high effort. |
Twice daily (after each half-day work shift) over the 12-day study protocol
|
|
Change in perceived fatigue score using a Numerical Rating Scale (NRS)
Periodo de tiempo: Twice daily (before and after each full work day) over the 12-day study protocol
|
Subjective physical fatigue is assessed using a 0 to 10 Numerical Rating Scale (NRS/EVN), where 0 represents very low fatigue and 10 represents very high fatigue. |
Twice daily (before and after each full work day) over the 12-day study protocol
|
|
User satisfaction score with the non-motorized DAP (ESAT questionnaire)
Periodo de tiempo: At the end of Phase B (Day 6 of wearing the device)
|
User satisfaction with the assistive device will be assessed using the 8-item Device subscale of the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0 / ESAT). Items are rated on a 5-point Likert scale from 1 to 5, yielding a total sum score ranging from 8 to 40, where higher scores indicate greater satisfaction |
At the end of Phase B (Day 6 of wearing the device)
|
|
Acceptability score based on the UTAUT model
Periodo de tiempo: Baseline (prior to Phase A1/B) and Post-Intervention (At the end of day 6 of phase B)
|
Technology acceptance will be assessed across the constructs of the Unified Theory of Acceptance and Use of Technology (UTAUT) questionnaire. Each item is rated on a 7-point Likert scale from 1 (strongly disagree) to 7 (strongly agree). Each item also belongs one of several subscales. Mean scores are calculated separately for each subscale, ranging from 1 to 7, where higher scores indicate greater technology acceptance. |
Baseline (prior to Phase A1/B) and Post-Intervention (At the end of day 6 of phase B)
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2026-A01360-51
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .